Quanterix Launches LucentAD Complete: A Breakthrough in Alzheimer’s Blood Testing

Revolutionizing Alzheimer’s Detection: LucentAD Complete Launches

Quanterix Corporation’s brand, Lucent Diagnostics, introduces LucentAD Complete, an advanced multi-marker blood test designed to enhance the detection of Alzheimer’s Disease (AD). This innovative test responds to the Alzheimer’s Association's updated criteria, which call for plasma p-Tau 217 tests with dual cutoffs for diagnosing AD. Historically, these criteria have left many patients in an “intermediate zone” of uncertainty, necessitating further invasive diagnostic procedures such as lumbar punctures or costly amyloid PET scans. LucentAD Complete aims to significantly reduce the number of patients falling into this category, potentially alleviating the burden of unnecessary invasive testing.

The LucentAD Complete test utilizes a proprietary algorithm to evaluate five critical biomarkers associated with Alzheimer’s: p-Tau 217, Aβ42/40, NfL, and GFAP. In rigorous clinical trials involving over 1,000 patients across three independent cohorts, the test has shown exceptional performance, adhering to guideline standards for blood-based diagnostics in Alzheimer’s. Notably, it outperforms traditional single-marker tests like p-Tau 217, marking a significant advancement in the field of cognitive disease detection. As Masoud Toloue, CEO of Quanterix, emphasizes, the launch of LucentAD Complete represents a pivotal moment for blood-based testing in Alzheimer’s, with results being shared at the prestigious Clinical Trials on Alzheimer’s Disease (CTAD) conference.

The development of this testing solution is bolstered by support from the Alzheimer’s Drug Discovery Foundation's Diagnostics Accelerator, highlighting the growing recognition of the need for a multi-biomarker approach in Alzheimer’s detection. Howard Fillit, MD, Co-Founder and Chief Science Officer at the foundation, points out that minimizing the intermediate zone reinforces the intricate nature of Alzheimer’s pathology. By bridging the gap between research and clinical application, Lucent Diagnostics positions itself at the forefront of cognitive disease diagnostics, offering healthcare providers a valuable tool for improved patient management.

In addition to the promising capabilities of LucentAD Complete, healthcare providers interested in the test can access further information on Lucent Diagnostics' dedicated website. The introduction of this multi-marker blood test marks a significant step toward more accessible and accurate Alzheimer’s diagnostics, reflecting a broader shift in the industry towards innovative and less invasive diagnostic solutions.